Managing Hypoglycemia (when combined) on Ozempic (semaglutide 0.5-2 mg): The HealthRX.com Step-by-Step Protocol

Does Ozempic cause low blood sugar on its own?

The Ozempic label reports its placebo-controlled hypoglycemia data separately for people taking Ozempic alone and people taking it on top of basal insulin with or without metformin [1].

In the 30-week monotherapy trial (129 people on placebo, 127 on 0.5 mg, 130 on 1 mg), documented symptomatic hypoglycemia at a glucose of 70 mg/dL or below occurred in 0%, 1.6% and 3.8% of those arms. Severe hypoglycemia, an episode that needed another person's help, occurred in 0% of all three arms, and severe or glucose-confirmed symptomatic events at 56 mg/dL or below occurred in 1.6% on placebo and 0% on both Ozempic doses [1].

A 2024 review written for emergency clinicians says hypoglycemia may occur when GLP-1 agonists are used with sulfonylureas or insulin [2].

What changes when basal insulin is part of the regimen?

The same label summary included people on basal insulin with or without metformin (132 on placebo, 132 on 0.5 mg, 131 on 1 mg). Documented symptomatic hypoglycemia at 70 mg/dL or below occurred in 15.2% of the placebo arm, 16.7% of the 0.5 mg arm and 29.8% of the 1 mg arm. Severe or glucose-confirmed symptomatic events at 56 mg/dL or below occurred in 5.3%, 8.3% and 10.7%, and severe episodes in 0%, 0% and 1.5% [1]. The label also notes that hypoglycemia was more frequent when Ozempic was used in combination with a sulfonylurea [1].

The label's hypoglycemia table covers the 0.5 mg and 1 mg doses. In a separate 40-week trial of 959 patients given Ozempic 1 mg or 2 mg as add-on to metformin with or without a sulfonylurea, the label reports no new safety signals [1].

What the Ozempic label says

The warning section states that people taking Ozempic with an insulin secretagogue such as a sulfonylurea, or with insulin, may have an increased risk of hypoglycemia including severe hypoglycemia. It says the risk may be lowered by a reduction in the dose of the sulfonylurea or other insulin secretagogue, or of insulin, and that patients on those drugs should be told about the risk and taught the signs and symptoms of hypoglycemia. The drug interactions section frames this as an action at the start of treatment: when Ozempic is initiated, consider reducing the dose of the insulin secretagogue or insulin. The label gives no percentage for the reduction [1].

The administration section adds one handling rule for people on insulin: the label says Ozempic and insulin should be given as separate injections and never mixed. Injecting in the same body region is acceptable, but not at adjacent sites [1].